Table 2 Patients’ characteristics of the UKB Non-ICB cohort and the UKB ICB cohort
Characteristic | UKB Non-ICB cohort | UKB ICB cohort |
|---|---|---|
Number N (%) | Number N (%) | |
All patients | 138 | 29 |
Age [years] (range) | 62.5 (32–89) | 62.3 (31–81) |
Gender | ||
Female | 24 (18.0) | 9 (31.0) |
Male | 115 (82.7) | 20 (69.0) |
Stage (UICC) | ||
I | 21 (15.2) | 0 (0) |
II | 22 (15.9) | 0 (0) |
III | 34 (24.6) | 0 (0) |
IV | 61 (44.2) | 29 (100) |
Disease origin | ||
Oropharynx | 60 (43.5) | 10 (34.5) |
Larynx | 31 (22.5) | 1 (3.4) |
Hypopharynx | 21 (15.2) | 4 (13.8) |
Oral cavity | 18 (13.0) | 8 (27.6) |
Nasal cavity and paranasal sinuses | 4 (2.9) | – |
Carcinoma of unknown primary | 4 (2.9) | 6 (20.7) |
HPV status in oropharyngeal carcinomas | ||
Positive | 27 (45.0) | 1 (10.0) |
Negative | 32 (53.3) | 6 (60.0) |
Unknown | 1 (1.7) | 3 (30.0) |
Immune checkpoint inhibitor | ||
Cemiplimab | – | 1 (3.4) |
Nivolumab | – | 27 (93.1) |
Nivolumab + ipilimumab | – | 1 (3.4) |
Response to immune checkpoint blockade | ||
Partial response | – | 4 (13.8) |
Stable disease | – | 7 (24.1) |
Progressive disease | – | 15 (51.7) |
Unknown | – | 3 (10.3) |
Immune-related adverse events | ||
Colitis | – | 1 (3.5) |
Hepatitis | – | 1 (3.5) |
Pneumonitis | – | 2 (6.9) |
Dermatitis and/or mucositis | – | 3 (10.3) |
None | – | 21 (72.4) |
Unknown | – | 2 (6.9) |